A pooled analysis of three randomized controlled trials shows the oral PCSK9 inhibitor enlicitide reduces LDL cholesterol by ...
Track late-stage GLP-1 innovation, once-weekly insulin, RNAi and gene therapies, plus licensing, partnerships and global clinical trial activity.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results